Emergent Biosolutions (EBS) Tops Q2 EPS by 6c, Posts FY11 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.23 --0%
EPS Growth %: -138.7%
Financial Fact:
Provision for (benefit from) income taxes: 13.17M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -138.7%
Financial Fact:
Provision for (benefit from) income taxes: 13.17M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q2 EPS of $0.40, $0.06 better than the analyst estimate of $0.34. Revenue for the quarter came in at $88.1 million versus the consensus estimate of $84.2 million.
Emergent Biosolutions sees FY2011 net income of $15 to $25 million. Emergent Biosolutions sees FY2011 revenue of $270-$290 million, versus the consensus of $326.68 million.
Emergent Biosolutions sees FY2011 net income of $15 to $25 million. Emergent Biosolutions sees FY2011 revenue of $270-$290 million, versus the consensus of $326.68 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- Infosys Limited (INFY) Reports In-Line Q3 EPS
- First Hawaiian (FHB) Misses Q3 EPS by 7c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
